Oral Mucositis - Pipeline Review, H1 2020

February 2020 | 128 pages | ID: O89300A1316EN
Global Markets Direct

Abstracts

Oral Mucositis - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Oral Mucositis - Pipeline Review, H1 2020, provides an overview of the Oral Mucositis (Gastrointestinal) pipeline landscape.

Oral mucositis is the most common type of mucositis. It is a debilitating complication of cancer surgery, chemotherapy and radiation. Symptoms include change in color, hyposalivation, a change in the integrity of the mucosa and the presence of edema on the lips and/or the tongue. Treatment included oral decontamination (mouth care) and oral debridement.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Oral Mucositis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Oral Mucositis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Oral Mucositis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Oral Mucositis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 10, 1 and 6 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Oral Mucositis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Oral Mucositis (Gastrointestinal).
• The pipeline guide reviews pipeline therapeutics for Oral Mucositis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Oral Mucositis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Oral Mucositis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Oral Mucositis (Gastrointestinal)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Oral Mucositis (Gastrointestinal).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Oral Mucositis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Oral Mucositis - Overview
Oral Mucositis - Therapeutics Development
Oral Mucositis - Therapeutics Assessment
Oral Mucositis - Companies Involved in Therapeutics Development
Oral Mucositis - Drug Profiles
Oral Mucositis - Dormant Projects
Oral Mucositis - Discontinued Products
Oral Mucositis - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Oral Mucositis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Oral Mucositis - Pipeline by Alivio Therapeutics Inc, H1 2020
Oral Mucositis - Pipeline by Allander Biotechnologies LLC, H1 2020
Oral Mucositis - Pipeline by BIOCND Inc, H1 2020
Oral Mucositis - Pipeline by Clevexel Pharma SAS, H1 2020
Oral Mucositis - Pipeline by Enzychem Lifesciences Corp, H1 2020
Oral Mucositis - Pipeline by Galera Therapeutics Inc, H1 2020
Oral Mucositis - Pipeline by Genekey Biotech Chengdu Co Ltd, H1 2020
Oral Mucositis - Pipeline by GlycoMira Therapeutics Inc, H1 2020
Oral Mucositis - Pipeline by Humanetics Corp, H1 2020
Oral Mucositis - Pipeline by Innovation Pharmaceuticals Inc, H1 2020
Oral Mucositis - Pipeline by Lakewood-Amedex Inc, H1 2020
Oral Mucositis - Pipeline by Matrix Biomed Inc, H1 2020
Oral Mucositis - Pipeline by Monopar Therapeutics Inc, H1 2020
Oral Mucositis - Pipeline by Oragenics Inc, H1 2020
Oral Mucositis - Pipeline by Soligenix Inc, H1 2020
Oral Mucositis - Pipeline by Spectrum Pharmaceuticals Inc, H1 2020
Oral Mucositis - Pipeline by Spherium Biomed SL, H1 2020
Oral Mucositis - Pipeline by Sunny Pharmtech Inc, H1 2020
Oral Mucositis - Dormant Projects, H1 2020
Oral Mucositis - Dormant Projects, H1 2020 (Contd..1), H1 2020
Oral Mucositis - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Oral Mucositis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020

COMPANIES MENTIONED

Alivio Therapeutics Inc
Allander Biotechnologies LLC
BIOCND Inc
Clevexel Pharma SAS
Enzychem Lifesciences Corp
Galera Therapeutics Inc
Genekey Biotech Chengdu Co Ltd
GlycoMira Therapeutics Inc
Humanetics Corp
Innovation Pharmaceuticals Inc
Lakewood-Amedex Inc
Matrix Biomed Inc
Monopar Therapeutics Inc
Oragenics Inc
Soligenix Inc
Spectrum Pharmaceuticals Inc
Spherium Biomed SL
Sunny Pharmtech Inc